Skip to main content Skip to main navigation menu Skip to site footer
Canadian Hematology Today: Science for the Real World
  • Home
  • Current
  • Archives
  • About
    • About the Journal
    • Editorial Board
    • Submissions
    • Journal Policies
  • Our Partners
  • Contact Us
  • Français
  • Login
  1. Home /
  2. Archives /
  3. Volume 1, Issue 3, November 2022

Volume 1, Issue 3, November 2022

					View Volume 1, Issue 3, November 2022
Published: 2022-11-01

Articles

  • Moving beyond chemotherapy in the management of follicular lymphoma

    Robert Kridel, MD, MPH, PhD
    8–11
    • PDF (en)
    • PDF (fr)
  • Hereditary hematologic malignancies: a Canadian perspective

    Amy M. Trottier, MD, FRCPC
    13–17
    • PDF (en)
    • PDF (fr)
  • The evolving treatment landscape of higher-risk MDS

    Mohamed Elemary, MD, MSc, PhD
    19–23
    • PDF (en)
    • PDF (fr)
  • Chronic Myeloid Leukemia: who should get a treatment-free trial and how?

    Sarit Assouline, MDCM, MSc, FRCPC
    25–28
    • PDF (en)
    • PDF (fr)
  • Evolving strategies in T-cell lymphoma

    Anca Prica, MD, MSc, FRCPC
    30–34
    • PDF (en)
    • PDF (fr)
Recent Articles
  • Moving beyond chemotherapy in the management of follicular lymphoma
  • Hereditary hematologic malignancies: a Canadian perspective
  • The evolving treatment landscape of higher-risk MDS
  • Chronic Myeloid Leukemia: who should get a treatment-free trial and how?
  • Evolving strategies in T-cell lymphoma

Summary

Journal title
Canadian Hematology Today.
Frequency
3 issues per year (March, June, October)
DOI Prefix
10.58931/cht

Open Access

Canadian Hematology Today is an open access journal, which means all its content is freely available without charge. Users are permitted to copy and redistribute the material in any medium or format for any noncommercial purpose, provided they cite the source.

Licence

© Canadian Hematology Today. Licensed under CC BY-NC-ND 4.0.

 

More information about the publishing system, Platform and Workflow by OJS/PKP.